This report provides all the information you require to better understand Cephalon and its partnering interests and activities over the past seven years.
Cephalon is once again on the acquisition trail
Cephalon has once again demonstrated tremendous business acumen and expanded its range of pharmaceutical products and services within the developed and emerging markets with the acquisition of Mepha for $615.4 million.
Teva Pharmaceuticals is a top pharmaceutical company based in Petach Tikva, Israel
During 2011 there were eleven partnering deal terminations where the value of the original deal was in excess of $500 million
Sorry, your search returned no results.
Acino will acquire Cephalon’s combined Middle East and African business for a total consideration of approximately EUR 80 million.
Cephalon, Inc. has announced it has signed a definitive merger agreement under which it will acquire all of the outstanding capital stock of Gemin X Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing first-in-class cancer therapeutics, for $225 million cash on a cash-free, debt-free basis.
Celator Pharmaceuticals has announced that it has agreed with Cephalon, Inc. to extend an existing research agreement into the next phase of development.
Cephalon will buy Mepha AG, the Swiss generic drugmaker owned by Germany’s Merckle family, for about $590 million (622.5 million Swiss francs) to diversify its product line and expand internationally.
Cephalon will pay BDC an upfront payment of $30 million and, assuming exercise of the option, an additional payment on the closing of the acquisition. BDC stockholders could also receive additional future payments related to regulatory and sales milestones. The option agreement is subject to customary closing conditions including the receipt of necessary BDC stockholder more »